Zimbabwe has declined a major American health deal valued at $367m (272 million pounds) over five years because of the United States' insistence on confidential biological samples.
This rejection came to light following a government memo from December was disclosed, indicating that President Emmerson Mnangagwa felt the deal was "unbalanced".
A government representative later clarified that the US was seeking genetic material for scientific study and profit but was not willing to share the benefits from any future treatments.
"We will now turn to the difficult and regrettable process of scaling back our health assistance in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the US had furnished over $1.9bn as health assistance to Zimbabwe during the past two decades.
A medical body in Zimbabwe has urged continued negotiations to reach a agreement agreeable to all parties so the nation's vital HIV programme can continue.
Broader Context
Zimbabwe's decision follows a similar situation in Kenya, where a court suspended a similar health funding agreement following legal challenges were filed about the security of citizens' health data.
After returning to the presidency last year, US President Donald Trump has reduced overseas assistance and shut down the key foreign aid agency.
USAID had overseen aid for the American government, but Trump claimed its expenditure was "wasteful" and his administration was pursuing government-to-government agreements to boost transparency and responsibility.
Based on reports, 16 African countries have so far signed similar health pacts, constituting more than $18.3bn in committed funds.
Specifics of the Rejected Agreement
This assistance for Zimbabwe would have funded "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this partnership could have provided immense advantages for Zimbabwean communities, especially the 1.2 million presently receiving antiretroviral therapy via US-supported initiatives," the Ambassador commented.
However, official spokesman Nick Mangwana maintained the proposed deal was "unequal".
"Zimbabwe was being asked to share its genetic material and health information indefinitely, with no equivalent promise of access to any medical innovations – like vaccines, diagnostics, or treatments – that could result from that provided information," his statement read.
"Effectively, our nation would provide the raw materials for scientific discovery with no certainty that the final treatments would be available to our citizens should a future pandemic arise."
Sovereignty and International Frameworks
He also noted that the American exit from the World Health Organization (WHO) and its push of one-on-one deals were upending frameworks previously established via the global organization.
Mangwana cited its Pandemic Benefit-Sharing system designed to manage future global health emergencies.
"This system is designed to guarantee that when a nation provides its samples, the resulting advantages – including vaccines and treatments – are shared equitably, not commercialised solely by those with the funds to create them."
Zimbabwe's reservations regarding the US deal "are not meant as opposition to America," he added.
"We welcome ongoing discussions with our American counterparts on how subsequent co-operation might be designed in a way that respects the sovereignty and interests of each country."
Medical Community Response
Medical experts stated it acknowledged the government's concerns, but recommended that talks need to persist given that much of the country's Aids initiatives depended on foreign aid.
"Where technical issues exist, such as those relating to data governance or agreement terms, these can often be resolved via technical clarification and negotiated safeguards," it added.
This impasse highlights the ongoing tensions between receiving vital foreign assistance and safeguarding a country's data in an ever more interconnected world.